Skip to main content
. 2016 Apr 26;14:123. doi: 10.1186/s12957-016-0886-5

Table 2.

Clinicopathological characteristics of stage III undifferentiated gastric adenocarcinoma in terms of histology type

Parameters MC (n = 39) SRCC (n = 261) PDC (n = 581) P value
Age (years), mean ± SD 64.5 ± 10.0 60.2 ± 13.7 62.7 ± 14.0 0.019
 Median 66.0 61.0 66.0
Sex 0.002
 Male 22 (56.4) 128 (49.0) 359 (61.8)
 Female 17 (43.6) 133 (51.0) 222 (38.2)
Tumor size (cm), mean ± SD 7.6 ± 3.9 6.0 ± 3.7 5.8 ± 3.1 0.006
 Median 7.0 5.0 5.0
Type of gastrectomy 0.696
 Total 13 (33.3) 96 (36.8) 226 (38.9)
 Subtotal 26 (66.7) 165 (63.2) 355 (61.1)
Extent of LN dissection 0.268
 <D2 13 (33.3) 71 (27.2) 190 (32.7)
 ≥D2 26 (66.7) 190 (72.8) 391 (67.3)
No. of LN retrieval, mean ± SD 29.2 ± 16.3 30.2 ± 16.2 28.6 ± 14.9 0.373
 Median 25.0 27.0 26.0
T status 0.627
 T2 2 (5.1) 6 (2.3) 10 (1.7)
 T3 1 (2.6) 5 (1.9) 9 (1.5)
 T4 36 (92.3) 250 (95.8) 562 (96.8)
LN status
 N0 2 (5.1) 1 (0.4) 13 (2.2) 0.118
 N1 8 (20.5) 41 (15.7) 86 (14.8)
 N2 11 (28.2) 52 (19.9) 136 (23.4)
 N3 18 (46.2) 167 (64.0) 346 (59.6)
Positive margins (R1 resection) 8 (20.5) 48 (18.4) 84 (14.5) 0.255
Lymphatic invasiona 0.442
 No 8 (21.1) 35 (13.5) 88 (15.4)
 Yes 30 (78.9) 225 (86.5) 484 (84.6)
Vascular invasiona 0.767
 No 30 (78.9) 204 (79.1) 439 (76.9)
 Yes 8 (21.1) 54 (20.9) 132 (23.1)
Perineural invasiona 0.003
 No 17 (45.9) 57 (22.2) 175 (30.8)
 Yes 20 (54.1) 200 (77.8) 394 (69.2)
Complicationsb 8 (20.5) 44 (16.9) 101 (17.4) 0.854
 Surgery-related 8 (20.5) 35 (13.4) 71 (12.2) 0.316
  Leakage 4 (10.3) 19 (7.3) 34 (5.9)
  Intra-abdominal abscess 4 (10.3) 12 (4.6) 28 (4.8)
  Wound infection 1 (2.6) 4 (1.5) 15 (2.6)
  Bleeding 1 (2.6) 8 (3.1) 9 (1.5)
  Delayed gastric emptying 0 1 (0.4) 4 (0.7)
  Others 0 3 (1.1) 3 (0.5)
 Surgery unrelated 1 (2.6) 16 (6.1) 48 (8.3) 0.275
  Pneumonia 0 2 (0.8) 12 (2.1)
  Cardiovascular event 0 5 (1.9) 6 (1.0)
  Sepsis 0 2 (0.8) 7 (1.2)
  Paralytic ileus 0 1 (0.4) 4 (0.7)
  Atelectasis 0 0 5 (0.9)
  Others 1 (2.6) 18 (6.9) 38 (6.5)
Hospital mortality 2 (5.1) 13 (5.0) 32 (5.5) 0.950
Chemotherapy 30 (76.9) 205 (78.5) 423 (72.8) 0.197

Figures are numbers with percentages in parentheses, unless otherwise stated

LN lymph node, MC mucinous carcinoma, SD standard deviation, PDC poorly differentiated carcinoma, SRCC signet ring cell carcinoma

aSome data were missing

bNumber of patients with event